FDA approves ThromboGenics' ocriplasmin

FDA approved a BLA from ThromboGenics N.V. (Euronext:THR) for Jetrea ocriplasmin to treat symptomatic vitreomacular adhesion (VMA). The company plans to launch the product in January 2013. The recombinant microplasmin, a truncated form of the natural human protein plasmin, is also under review in the EU. ThromboGenics was up EUR 1.40 to EUR 38.40 on Thursday. ...